SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

19 Oct 2023 Evaluate
The company witnessed a 9.41% growth in the revenue at Rs. 4733.90 millions for the quarter ended September 2023 as compared to Rs. 4326.90 millions during the year-ago period.The Net Profit of the company slipped to Rs. 331.40 millions from Rs. 496.40 millions, a decline of -33.24% on QoQ basis.A decline of 735.40 millions was observed in the OP in the quarter ended September 2023 from 881.00 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 4733.90 4326.90 9.41 8962.70 8405.90 6.62 16666.90 15397.20 8.25
Other Income 11.20 3.40 229.41 15.30 14.70 4.08 23.30 23.20 0.43
PBIDT 735.40 881.00 -16.53 1368.60 1605.30 -14.74 2872.20 3293.20 -12.78
Interest 81.00 52.50 54.29 158.80 93.80 69.30 250.30 141.40 77.02
PBDT 654.40 828.50 -21.01 1209.80 1511.50 -19.96 2621.90 3151.80 -16.81
Depreciation 214.10 156.50 36.81 412.80 357.50 15.47 706.00 789.50 -10.58
PBT 440.30 672.00 -34.48 797.00 1154.00 -30.94 1915.90 2362.30 -18.90
TAX 108.90 175.60 -37.98 206.20 272.90 -24.44 502.30 817.10 -38.53
Deferred Tax -6.20 -16.80 -63.10 5.60 -73.50 -107.62 -49.70 -73.40 -32.29
PAT 331.40 496.40 -33.24 590.80 881.10 -32.95 1413.60 1545.20 -8.52
Equity 184.30 184.30 0.00 184.30 184.30 0.00 184.30 184.30 0.00
PBIDTM(%) 15.53 20.36 -23.70 15.27 19.10 -20.04 17.23 21.39 -19.43

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×